Figure 3
Figure 3. OS in 224 patients with relapse during or after chemotherapy, Ph−/BCR-ABL− ALL, and no CNS involvement for whom data on salvage therapy were available. (A) OS according to response to first salvage: CR, n = 95 (solid line), 47% ± 6% after 3 years, median 33.3 months; no CR, n = 129 (dashed line); 13% ± 3% after 3 years, median 5.8 months (P < .0001). (B) OS according to response to second salvage: CR, n = 27 (solid line), 35% ± 9% after 3 years, median 14.2 months; no CR, n = 55 (dashed line), 8% ± 4% after 3 years, median 6.6 months (P = .0003).

OS in 224 patients with relapse during or after chemotherapy, Ph/BCR-ABL ALL, and no CNS involvement for whom data on salvage therapy were available. (A) OS according to response to first salvage: CR, n = 95 (solid line), 47% ± 6% after 3 years, median 33.3 months; no CR, n = 129 (dashed line); 13% ± 3% after 3 years, median 5.8 months (P < .0001). (B) OS according to response to second salvage: CR, n = 27 (solid line), 35% ± 9% after 3 years, median 14.2 months; no CR, n = 55 (dashed line), 8% ± 4% after 3 years, median 6.6 months (P = .0003).

Close Modal

or Create an Account

Close Modal
Close Modal